Detailed Narrative
Q4 FY26 Performance Overview
Kimball Electronics reported Q4 FY26 net sales of $371.6 million, a 2% year-over-year decline but a 5% sequential increase. Adjusted operating income was $18.1 million (4.9% of net sales), down from $19.6 million (5.2%) in Q4 FY25. The gross margin rate improved by 90 basis points to 8.9%, primarily due to favorable mix. The company generated $42.4 million in cash from operations, reducing debt to its lowest level in over four years at $116.6 million.
Medical Segment Growth and Strategy
The Medical segment was a key highlight, with Q4 FY26 sales of $109 million (29% of total), up 1% year-over-year. For the full fiscal year, Medical sales grew over 10% (normalized). Management expects Medical to continue leading organic growth in FY27, projecting high single to low double-digit growth and comprising approximately 35% of total company sales. The recent acquisition of Helvoet Polymer Technologies and the build-out of the Indianapolis CDMO facility are central to this strategy, with production equipment being installed and early production expected by calendar year-end.
Automotive and Industrial Segment Trends
Automotive sales in Q4 FY26 were $170 million (46% of total), down 3% year-over-year, primarily due to lower EV demand in North America, partially offset by mid-single-digit increases in Poland and Romania from new steering and braking programs. For the full year, Automotive was down 7%, but successive 3% declines in the back half suggest stabilization. Industrial sales totaled $93 million (25% of total), a 5% decrease year-over-year, mainly from lower HVAC demand in North America, partially offset by higher smart meter sales in Europe.
Balance Sheet Strength and Capital Allocation
The company ended FY26 with $88.9 million in cash and cash equivalents and $411.3 million in available liquidity. Borrowings were reduced to $116.6 million, the lowest in over four years. Management aims for a long-term leverage ratio of 1.5x to 2x debt to EBITDA, balancing organic investment, share repurchases (with $24.4 million remaining authorization), and maintaining dry powder for strategic inorganic opportunities. The Helvoet acquisition, which closed July 1, will impact Q1 FY27 balances.
Helvoet Integration and Synergies
The integration of Helvoet, acquired on July 1, 2026, is progressing well, with a focus on unlocking top-line synergies. Customer interest has been strong, with demand for Helvoet's operations in Tilburg and Pune, and requests to tour the Indianapolis facility. The acquisition provides Helvoet with a U.S. footprint and Kimball with expanded capabilities in Europe and India, facilitating larger co-development programs. Management expects Helvoet to contribute $60 million in revenue in FY27, with currency translation being a factor in its growth rate.
Indianapolis CDMO Facility Ramp-up
The new medical CDMO facility in Indianapolis is undergoing equipment installation, with qualification of manufacturing processes expected to start in the fall. Early production is anticipated by the end of calendar year 2026, and the full move from the existing campus is projected to be completed within 18 months. The dilutive impact of the ramp-up in FY27, estimated at $6.5 million to $7 million, is expected to be roughly offset by the accretive benefit from Helvoet.